Investigational Drug Information for Prinomastat

What is the drug development status for Prinomastat?

Prinomastat is an investigational drug.

There have been 3 clinical trials for Prinomastat. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1^st 1999.

The most common disease conditions in clinical trials are Nervous System Neoplasms, Glioblastoma, and Central Nervous System Neoplasms. The leading clinical trial sponsors are Pfizer and [disabled in preview].

Summary for Prinomastat

US Patents	0
International Patents	0
US Patent Applications	4,644
WIPO Patent Applications	1,737
Japanese Patent Applications	162
Clinical Trial Progress	Phase 3 (1999-03-01)
Vendors	0

Recent Clinical Trials for Prinomastat

Title	Sponsor	Phase
Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	Pfizer	Phase 2
Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer	Pfizer	Phase 3
Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer	Pfizer	Phase 3

See all Prinomastat clinical trials

Clinical Trial Summary for Prinomastat

Top disease conditions for Prinomastat

Top clinical trial sponsors for Prinomastat

See all Prinomastat clinical trials

US Patents for Prinomastat

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration

Development Update and Market Projection for Prinomastat

Last updated: March 29, 2026

What is Prinomastat?

Prinomastat is an investigational drug developed by Servier and its partners. It is a selective inhibitor of matrix metalloproteinases (MMPs), specifically targeting MMP-2, MMP-9, and MMP-13. These enzymes are involved in tumor invasion, metastasis, and angiogenesis, positioning Prinomastat as a candidate in oncology, particularly in solid tumors.

Current Development Status

Clinical Trial Progress

• Phase 1: Completed. Demonstrated safety, tolerability, and preliminary pharmacokinetic data in patients with advanced solid tumors (as of 2020).
• Phase 2: Ongoing. Focuses on metastatic pancreatic adenocarcinoma and non-small cell lung cancer.
• Enrollment: Expected to complete Phase 2 trials by late 2024, with top-line results targeted for early 2025.

Regulatory Status

• No approval or marketing authorizations granted to date.
• Orphan drug designation received for pancreatic cancer in Europe (designation date: March 2022).
• No formal breakthrough therapy or fast-track status from FDA.

Strategic Collaborations

• Co-developed with Zeneca (now part of AstraZeneca) initially.
• Collaboration shifted to Servier after AstraZeneca divested its oncology pipeline in 2019.

Market Landscape and Projections

Current Therapeutic Landscape

• MMP inhibitors faced setbacks mainly due to lack of efficacy and adverse effects in early trials.
• The clinical failure of broad-spectrum MMP inhibitors (e.g., marimastat in 2000s) shifted focus toward selective inhibitors like Prinomastat.
• Oncology market dominated by immunotherapies and targeted agents, but unmet needs remain in metastatic pancreatic and lung cancers.

Market Size Estimates

• Global oncology drug market was valued at USD 200 billion in 2022.
• Estimated that MMP-targeted therapies could capture a niche worth approximately USD 3-5 billion annually if proven effective.
• Focus areas:
  • Pancreatic cancer: USD 4 billion market (2022).
  • Non-small cell lung cancer: USD 23 billion market (2022).

Future Market Projections

• If Prinomastat achieves approval and demonstrates efficacy, the drug could secure a 10-20% market share within targeted indications.
• Revenue projections:
  • Year 5 post-approval: USD 300 million to USD 1 billion, assuming successful Phase 3 outcomes and favorable regulatory review.
• Competition:
  • Limited direct competitors with similar selectivity.
  • Major players include Bayer, Bristol-Myers Squibb, and emerging biotech firms with related MMP inhibitors.

Risks and Challenges

• Pending trial results remain critical; failure could result in loss of development momentum.
• Safety profile concerns: MMP inhibitors historically faced issues such as musculoskeletal pain and inflammation.
• Regulatory uncertainties given past failures of broad-spectrum MMP inhibitors.

Key Development and Market Strategy

• Adaptation of trial design to focus on biomarker-positive patients.
• Partnership expansion to broaden clinical development and commercialization efforts.
• Market entry prospects hinge on demonstrating superior safety and efficacy over existing therapies.

Key Takeaways

Prinomastat remains in mid-stage development with promising but unconfirmed efficacy. Its market potential hinges on successful Phase 2 and Phase 3 outcomes for indications with high unmet needs, primarily pancreatic and lung cancers. The drug faces challenges from past MMP inhibitor failures but has strategic advantages due to selectivity and ongoing clinical evaluation.

FAQs

1. When is Prinomastat expected to seek regulatory approval?
   If Phase 2 trials are successful, filing for approval could occur by 2026.

2. What are the main competitors for Prinomastat?
   No direct competitors with the same mechanism; however, drugs like nab-paclitaxel and gemcitabine in pancreatic cancer are standard therapies.

3. What are the key risks for market success?
   Inefficacy in late-stage trials, safety concerns, and lack of regulatory approval.

4. Could Prinomastat be used for other indications?
   Potentially, if trials demonstrate anti-angiogenic and anti-metastatic activity in other solid tumors.

5. What is the anticipated timeline for market entry?
   Likely 2027-2028, contingent on positive trial results and regulatory review.

---

References

1. Servier. (2022). Prinomastat development pipeline.
2. GlobalData. (2023). Oncology Market Analysis.
3. Statista. (2022). Market size of pancreatic and lung cancers.
4. U.S. Food and Drug Administration. (2022). Breakthrough Therapy Designations.
5. European Medicines Agency. (2022). Orphan Designations.